Atlas Trials

Zydus Therapeutics Inc.

19 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Zydus Therapeutics Inc.

RecordFirmDate
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy (NCT07424677)Zydus Therapeutics Inc.2026-06-01
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (NCT07216235)Zydus Therapeutics Inc.2026-03-24
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis (NCT07023835)Zydus Therapeutics Inc.2025-09-17
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease (NCT06825559)Zydus Therapeutics Inc.2025-08-05
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (NCT06427395)Zydus Therapeutics Inc.2024-07-16
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US (NCT05211284)Zydus Therapeutics Inc.2022-12-08
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (NCT05133336)Zydus Therapeutics Inc.2022-04-01
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease (NCT05045482)Zydus Therapeutics Inc.2021-10-21
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis (NCT05011305)Zydus Therapeutics Inc.2021-08-18
A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function (NCT04446507)Zydus Therapeutics Inc.2020-07-27
Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function (NCT04469920)Zydus Therapeutics Inc.2020-07-16
Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects (NCT04112446)Zydus Therapeutics Inc.2019-09-20
A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers (NCT04045769)Zydus Therapeutics Inc.2019-08-19
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis (NCT03863574)Zydus Therapeutics Inc.2019-06-12
Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD) (NCT03639623)Zydus Therapeutics Inc.2019-02-25
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) (NCT03617263)Zydus Therapeutics Inc.2019-02-12

Track Zydus Therapeutics Inc. automatically

Every clearance here is in the API, with alerts when new ones post.